Enveric Biosciences reports positive preclinical results for depression/anxiety drug candidate EB-003.

Enveric Biosciences (ENVB) reported encouraging preclinical safety and pharmacology results for its lead drug candidate, EB-003, aimed at treating mental health disorders like depression and anxiety. The compound selectively targets serotonergic receptors with minimal off-target effects, reducing safety concerns. Despite these positive results, the company's stock fell over 10%. Enveric plans to file an Investigational New Drug application by Q3 2025 and begin clinical development by year-end.

October 15, 2024
3 Articles